The Development of MetAP-2 Inhibitors in Cancer Treatment

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|19|7|1021-1035

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.19, Iss.7, 2012-01, pp. : 1021-1035

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Role of COX-2 in Oral Cancer Development, and Chemoprevention/ Treatment of Oral Cancer by Selective COX-2 Inhibitors

By  

Current Pharmaceutical Design, Vol. 11, Iss. 14, 2005-05 ,pp. : 1771-1777

Bentham Science Publishers

Access to resources Recommend Favorite

Development of c-MET pathway inhibitors

By Liu Xiangdong   Newton Robert C   Scherle Peggy A  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 9, 2011-09 ,pp. : 1225-1241

Informa Healthcare

Access to resources Recommend Favorite

Akt inhibitors in clinical development for the treatment of cancer

By Pal Sumanta Kumar   Reckamp Karen   Yu Hua   Figlin Robert A  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 11, 2010-11 ,pp. : 1355-1366

Informa Healthcare

Access to resources Recommend Favorite

CDK inhibitors in clinical development for the treatment of cancer

By Fischer Peter M   Gianella-Borradori Athos  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 6, 2003-06 ,pp. : 955-970

Informa Healthcare

Access to resources Recommend Favorite

Recent advances in the development of telomerase inhibitors for the treatment of cancer

By Perry P.J.   Jenkins T.C.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 12, 1999-12 ,pp. : 1981-2008

Informa Healthcare

Access to resources Recommend Favorite